Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Cardiac failure congestive 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Left ventricular dysfunction 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Total: 117/382 (30.63%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Anaemia 3/382 (0.79%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Disseminated intravascular coagulation 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Febrile neutropenia 11/382 (2.88%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Neutropenia 20/382 (5.24%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Thrombocytopenia 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Atrial fibrillation 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Atrial flutter 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Cardiac failure congestive 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Total: 5/32 (15.63%) secondary trial: Left ventricular dysfunction 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Total: 285/752 (37.90%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Anaemia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Disseminated intravascular coagulation 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Febrile neutropenia 51/752 (6.78%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Neutropenia 47/752 (6.25%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Thrombocytopenia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Atrial fibrillation 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Atrial flutter 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Cardiac failure congestive 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Left ventricular dysfunction 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Total: 117/382 (30.63%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Anaemia 3/382 (0.79%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Disseminated intravascular coagulation 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Febrile neutropenia 11/382 (2.88%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Neutropenia 20/382 (5.24%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Thrombocytopenia 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Atrial fibrillation 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Atrial flutter 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Cardiac failure congestive 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Febrile neutropenia 1/32 (3.13%) secondary trial: Left ventricular dysfunction 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Total: 285/752 (37.90%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Anaemia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Disseminated intravascular coagulation 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Febrile neutropenia 51/752 (6.78%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Neutropenia 47/752 (6.25%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Thrombocytopenia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Atrial fibrillation 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Atrial flutter 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Cardiac failure congestive 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Left ventricular dysfunction 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Total: 117/382 (30.63%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Anaemia 3/382 (0.79%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Disseminated intravascular coagulation 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Febrile neutropenia 11/382 (2.88%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Neutropenia 20/382 (5.24%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Thrombocytopenia 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Atrial fibrillation 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Atrial flutter 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Cardiac failure congestive 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Supraventricular tachycardia 1/32 (3.13%) secondary trial: Left ventricular dysfunction 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Total: 285/752 (37.90%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Anaemia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Disseminated intravascular coagulation 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Febrile neutropenia 51/752 (6.78%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Neutropenia 47/752 (6.25%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Thrombocytopenia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Atrial fibrillation 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Atrial flutter 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Cardiac failure congestive 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Left ventricular dysfunction 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Total: 117/382 (30.63%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Anaemia 3/382 (0.79%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Disseminated intravascular coagulation 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Febrile neutropenia 11/382 (2.88%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Neutropenia 20/382 (5.24%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Thrombocytopenia 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Atrial fibrillation 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Atrial flutter 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Cardiac failure congestive 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Hypersensitivity 2/32 (6.25%) secondary trial: Left ventricular dysfunction 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Total: 285/752 (37.90%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Anaemia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Disseminated intravascular coagulation 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Febrile neutropenia 51/752 (6.78%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Neutropenia 47/752 (6.25%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Thrombocytopenia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Atrial fibrillation 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Atrial flutter 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Cardiac failure congestive 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Left ventricular dysfunction 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Total: 117/382 (30.63%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Anaemia 3/382 (0.79%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Disseminated intravascular coagulation 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Febrile neutropenia 11/382 (2.88%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Neutropenia 20/382 (5.24%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Thrombocytopenia 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Atrial fibrillation 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Atrial flutter 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Cardiac failure congestive 0/382 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Catheter site infection 1/32 (3.13%) secondary trial: Left ventricular dysfunction 1/382 (0.26%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Total: 285/752 (37.90%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Anaemia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Disseminated intravascular coagulation 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Febrile neutropenia 51/752 (6.78%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Neutropenia 47/752 (6.25%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Thrombocytopenia 2/752 (0.27%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Atrial fibrillation 1/752 (0.13%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |
dbed5471-c2fc-45b5-b26f-430c9fa37a37 | primary trial: Confusional state 1/32 (3.13%) secondary trial: Atrial flutter 0/752 (0.00%) Heart-related adverse events were recorded in both the primary trial and the secondary trial. | 1 |